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Abstract
Background: There are numerous non-biologic and biologic disease-modifying anti-rheumatic drugs (bDMARDs)
for rheumatoid arthritis (RA). Typical sequences of bDMARDs are not clear. Future treatment policies and trials
should be informed by quantitative estimates of current treatment practice.
Methods: We used data from Corrona, a large real-world RA registry, to develop a method for quantifying
sequential patterns in treatment with bDMARDs. As a proof of concept, we study patients who eventually use
tocilizumab monotherapy (TCZm), an IL-6 antagonist with similar benefits used as monotherapy or in
combination. Patients starting a bDMARD were included and were followed using a discrete-state Markov
model, observing changes in treatments every 6 months and determining whether they used TCZm. A
supervised machine learning algorithm was then employed to determine longitudinal patient factors
associated with TCZm use.
Results: 7300 patients starting a bDMARD were followed for up to 5 years. Their median age was 58 years,
78% were female, median disease duration was 5 years, and 57% were seropositive. During follow-up, 287
(3.9%) reported use of TCZm with median time until use of 25.6 (11.5, 56.0) months. Eighty-two percent of
TCZm use began within 3 years of starting any bDMARD. Ninety-three percent of TCZm users switched from
TCZ combination, a TNF inhibitor, or another bDMARD. Very few patients are given TCZm as their first DMAR
D (0.6%). Variables associated with the use of TCZm included prior use of TCZ combination therapy, older
age, longer disease duration, seronegative, higher disease activity, and no prior use of a TNF inhibitor.
Conclusions: Improved understanding of treatment sequences in RA may help personalize care. These
methods may help optimize treatment decisions using large-scale real-world data.
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Background
Rheumatoid arthritis (RA) is a chronic systemic auto-
immune inflammatory condition that involves the upreg-
ulation of various cytokines and auto-antibodies over
time [1]. While the precise “cause” of RA is unknown,
there are strong genetic alleles and several key environ-
mental exposures that strongly associate with the risk of
RA [2]. The immunobiology of RA has been well de-
scribed, and many treatments developed that inhibit key
aspects of the inflammatory cascade [1]. The majority of
patients with RA find treatments that reduce disease ac-
tivity and pain, but not all patients are so lucky and the
path to successful treatment may be long and littered
with disease-modifying anti-rheumatic drugs (DMARDs)
that do not work [3]. Thus, it is surprising that relatively
few studies have focused on sequences of RA treatments
[4].
Recommendations regarding RA treatment suggest
starting with conventional synthetic DMARDs
(csDMARDs) [5, 6], but then there is little evidence
about which bDMARD should be tried next. The evi-
dence grows even scanter as one considers second- or
third-line bDMARDs [7]. Sequential decisions may be
determined by previous treatment response, comorbidi-
ties, patient and provider preferences, and insurance.
Optimizing sequential decisions through clinical trials is
difficult since the number of possible sequences is large.
A pragmatic approach is to first identify and quantify
patterns in current treatment practice and then evaluate
these in comparative trials.
In this work, we studied sequences of RA treatments
using discrete-state Markov models for high-level statis-
tics and logistic regression for determinants of treatment
choice. Markov models describe the probabilities of
moving from one state to another in a discrete dynam-
ical system using a state transition matrix [8]. These
have been widely used in econometric modeling, cost-
effectiveness modeling, and in some clinical areas [9–
11], but they have played little role in personalizing
treatment strategies in RA. We use logistic models to
discriminate between patients on the same treatment
who are moved to different drugs in the next stage.
In this set of analyses, we examined pathways to toci-
lizumab monotherapy (TCZm). Monotherapy with this
agent has proven efficacy over other bDMARDs used
without a csDMARD [12–15]. Since many patients find
using monotherapy preferable, we focused on TCZm
and examined the sequences to and predictors of its use
in a large real-world dataset from the US, Corrona.
While this set of analyses may have specific practical
relevance for TCZm treatment, it should be considered
as an exploration of methods that can be considered
when evaluating sequences of treatment for a chronic
disease like RA. To illustrate this point, for comparison,
we apply the same methodology to briefly characterize
common sequences leading to monotherapy with TNF
inhibitors. We did not assess the optimization of treat-
ment strategies but rather how to analyze sequential
data in ways that can guide experiment design for such
optimization.
Methods
Study design and population
We examined transitions of RA treatments among a co-
hort of patients initiating a bDMARD. All patients were
enrolled in the Corrona RA registry between 2002 and
2019, a large real-world data source in the USA [16]. Pa-
tients were followed longitudinally for up to 5 years to
determine transitions between bDMARDs, specifically
examining if they started TCZm, subcutaneous or intra-
venous. The visit prior to the first report of a bDMARD
initiation was considered the baseline, and the visits dur-
ing the ensuing 5 years were the follow-up period. The
probabilities of transitioning from one type of bDMARD
to another were calculated at 6-month intervals during
follow-up. Predictors of TCZm and TCZ combination
therapy (TCZc) were assessed using regression models
and machine learning algorithms.
Outcome of interest
The primary outcome of interest was the initiation of
TCZm and the sequence of RA treatments leading to
TCZm. This was defined through the use of the case report
forms that are collected every 4–6months by the rheuma-
tology clinical site in Corrona. Monotherapy was defined as
no other DMARD treatment marked on the case report
form at the time of TCZ use; we did not include sarilumab
(another IL-6 antagonist) in these analyses.
Other RA treatments considered in the sequence ana-
lyses and the modeling included TCZc (TCZ with a
csDMARD), TNF inhibitors without TCZ +/− csDMARD,
non-TNF non-TCZ bDMARDs +/− csDMARDs, and
csDMARDs without a bDMARD. csDMARDs were in-
cluded as some patients transition back to a csDMARD
after trying a bDMARD. JAK inhibitors (here Xeljanz)
were counted as bDMARDs since they are used sequen-
tially after synthetic DMARDs and target-specific immune
pathways. We also included no DMARDs as a possible RA
treatment state.
Covariates
Potential predictors of TCZm use were assessed at the
visit prior to starting any bDMARD (baseline) and also
during follow-up. We considered patient’s age and sex at
the baseline visit. We also considered a number of RA
characteristics at baseline: disease duration, serologic
status, erosion status, clinical disease activity index
(CDAI) [17], health assessment questionnaire (HAQ)
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[18], and prior DMARDs. CDAI, HAQ, and prior
DMARDs were updated during follow-up. In addition,
we examined comorbidities at baseline. These were ori-
ginally considered as individual comorbidities, and then,
they were collapsed into a simple count variable, giving
each condition a similar weight. These comorbidities are
listed in Table 1.
At baseline, some patients had missing serologic sta-
tus. We used all available information on rheumatoid
factor and anti-CCP status up through the baseline visit.
However, serologic status remained missing on 8.9% and
these values were categorized as missing in the analyses.
The HAQ was missing at baseline for some patients; we
used the non-missing value immediately prior to the
baseline visit for such patients.
Statistical analyses
We described the baseline characteristics of patients in-
cluded in the study cohort. Median values or numbers
and percentages were assessed. The Markov transition
Table 1 Characteristics of patients in Corrona who initiated a biologic DMARD, 2002–2019
Biologic DMARD, any TCZ, any TCZm
N 7300 676 287
Age, median (IQR), years 58 (49, 66) 56 (46, 64) 56 (47, 65)
Female, n (%) 5667 (77.63) 539 (78.73) 233 (81.18)
Disease duration, median (IQR), years 5 (2, 12) 4 (1, 12) 5 (1, 12)
Seropositive*, n (%) 3783 (56.81) 303 (47.20) 131 (48.34)
Conventional DMARD use, n (%) 5994 (82.11) 521 (77.07) 200 (69.69)
Methotrexate 4873 (66.75) 414 (61.24) 149 (51.92)
Non-methotrexate csDMARDs 2414 (33.07) 232 (34.32) 95 (33.10)
Glucocorticoid use, any 2482 (34.00) 242 (35.80) 104 (36.24)
CDAI, median (IQR)** 15.6 (7.5, 25.8) 18.0 (9.9, 28.2) 18.4 (8.7, 28.0)
Remission, n (%) 642 (8.79) 36 (5.33) 16 (5.57)
Low disease activity, n (%) 1729 (23.68) 133 (19.67) 64 (22.30)
Moderate disease activity, n (%) 2362 (32.36) 226 (33.43) 86 (29.97)
High disease activity, n (%) 2298 (31.48) 265 (39.20) 113 (39.37)
HAQ, median (IQR)** 0.86 (0.25, 1.38) 1.00 (0.50, 1.63) 1.00 (0.50, 1.63)
Comorbidities, n (%)
Anemia 105 (1.44) 21 (3.11) 10 (3.48)
Asthma 113 (1.55) 9 (1.33) 5 (1.74)
Depression 317 (4.34) 38 (5.62) 17 (5.92)
Diabetes mellitus 279 (3.82) 30 (4.44) 12 (4.18)
Diarrhea 76 (1.04) 10 (1.48) 4 (1.39)
Dyspepsia 96 (1.32) 10 (1.48) 8 (2.79)
Fibromyalgia 111 (1.52) 18 (2.66) 8 (2.79)
Hepatic event 10 (0.14) 2 (0.30) 1 (0.35)
Hyperlipidemia 255 (3.49) 27 (3.99) 15 (5.23)
Hypertension 942 (12.90) 91 (13.46) 41 (14.29)
Nausea 86 (1.18) 9 (1.33) 4 (1.39)
Cancer 139 (1.90) 14 (2.07) 4 (1.39)
Stroke 61 (0.84) 7 (1.04) 4 (1.39)
Ulcer 188 (2.58) 21 (3.11) 12 (4.18)
Miscellaneous# 1313 (17.99) 98 (14.50) 43 (14.98)
Disease duration information missing in 31 subjects
HAQ Health Assessment Questionnaire version, TCZ tocilizumab, TCZm tocilizumab monotherapy, IQR inter-quartile range, DMARD disease-modifying
anti-rheumatic drug
*Seropositive defined as a positive rheumatoid factor or anti-CCP antibody, based on 6659 non-missing values
**Clinical disease activity index (CDAI) categories defined as remission (CDAI < 2.8), low (CDAI 2.9–10.0), moderate (CDAI 10.1–22.0), and high (CDAI > 22.1)
#Miscellaneous includes drug toxicity, fracture, and other less common comorbidities
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matrix for DMARD status was assembled using 6-month in-
tervals over the 5 years of follow-up. We examined the tran-
sition probabilities for each bDMARD category. After
starting a bDMARD, some patients had 6-month intervals
with no DMARD or only csDMARDs noted; we also
assessed the probability of no DMARD or only a csDMARD.
Based on these probabilities, we assessed the most common
sequences of medications used prior to TCZm.
To further characterize patient characteristics associ-
ated with TCZm use, we constructed regression models
for discriminating between patients who end up on dif-
ferent treatments. Since we noticed that most patients
who used TCZm had used TCZc, we examined models
that used both TCZ states as dependent variables. Vari-
ables were included based on forward selection: univari-
able logistic models considered one baseline variable at a
time; variables with p < 0.2 were advanced to
multivariable-adjusted regression. We built the baseline-
only logistic regression model with selected baseline fac-
tors. To improve the prediction of TCZ use, we included
variables characterized during follow-up using a linear
logistic model with repeated measurements (PROC
GLMMIX, SAS V9.0). We measured the within-person
correlation with robust covariance estimates. Unlike a
typical epidemiologic model focusing on baseline predic-
tors, models with updated variables allow one to con-
sider sequential changes in patient characteristics that
may influence treatment decisions.
Results
We identified 7300 patients with RA in the Corrona
registry who initiated a bDMARD after entry. Character-
istics of these patients are described in Table 1. The me-
dian age at study baseline was 57.3 years, 77.6% were
female, the median disease duration was 5 years, and
56.8% were seropositive. At baseline, 82.1% reported the
use of another csDMARD (e.g., methotrexate) and 33.1%
reported the use of glucocorticoids.
Of the patients starting bDMARDs during Corrona
follow-up, 676 (9.3%) initiated TCZ at some point and
287 (3.9%) reported use of TCZm. The median time
until any use of TCZ was 17.5 months and 25.6 (IQR
11.5, 56.0) months until TCZm. The median number of
bDMARDs between initiation and TCZ was 1 (range 0–
6); for TCZm the median was also 1 (range 1–5).
Fig. 1 Sequences of biologic DMARDs among patients in Corrona who eventually used tocilizumab monotherapy. Each colored line represents a
common sequence of treatments used by a subset of Corrona patients ending with TCZm use. For example, the left-most orange line illustrates
the sequence bDMARD->TNF combo->Nonbiologics->TNF combo->TCZm. The number of markers on each line is equal to the number of
treatments in the trajectory, looking back at most 4 steps before TCZm treatment. The thickness of a line correlates linearly with the number of
patients following the corresponding sequence. The colored legend describes the sequences of DMARD treatments for these patients. Gray lines
illustrate sequences with fewer than 4 occurrences. Abbreviations: TCZ, tocilizumab; DMARD, disease modifying anti-rheumatic drug; bDMARD,
biologic DMARD; mono, DMARD monotherapy; combo, combination DMARD therapy
Solomon et al. Arthritis Research & Therapy           (2021) 23:26 Page 4 of 9
Eighty-two percent of TCZm use began within 3 years
of starting any bDMARD; 93% of TCZm users switched
from TCZ combination, a TNF inhibitor, or another
bDMARD. Common sequences of DMARDs until
TCZm use, going back at most 4 treatments, are illus-
trated in Fig. 1. Each line represents a different trajectory
of treatments (color) and a different number of instances
(thickness). Only trajectories ending with TCZm are in-
cluded. Common sequences from the initiation of a
bDMARD through TCZm use include TNFi to TCZ
combination to TCZm (5.9%), TNFi to another
bDMARD to TCZm (9.8%), and TNFi to TCZm (13.9%).
Very few patients are given TCZm as their first DMARD
(0.6%) or their first bDMARD (0.9%). The full 5 years of
transition probabilities after initiation of a bDMARD are
described in Table 2. For comparison with Fig. 1, we ap-
plied the same methodology to illustrate common
DMARD sequences leading to TNF inhibitor monother-
apy (see Fig. 2). We see that such sequences in current
practice are vastly dominated by transitions from TNFi
combination therapy with nonbiologic DMARDs to
TNFi monotherapy (72%). Sequences in which
bDMARDs precede TNFi monotherapy are compara-
tively rare in this sample (9.6%).
To better understand the factors associated with the
use of TCZ and specifically TCZm, we conducted two
different sets of regression models. First, we examined
baseline variables only as predictors of any TCZ use and
of TCZm. Similar variables were found to be associated
with both outcomes (see Tables 3 and 4). These include
age, serologic status, and use of csDMARDs at baseline.
In a separate set of regression models, we allowed
post-baseline variables (accumulation of comorbidities,
disease activity, and prior DMARD use) to enter the
regression, updating these variables over time. Variables
associated with the use of any TCZ included older age,
longer disease duration, seronegative, higher disease ac-
tivity, no prior use of a TNF inhibitor, and more comor-
bidities (see Table 4).
Finally, we focused on predictors of TCZm in longitu-
dinal analyses (see Table 3). As with any use of TCZ,
predictors of TCZm included older age, longer disease
duration, higher disease activity, and no prior use of a
TNF inhibitor. The use of TCZc was a very strong pre-
dictor of TCZm use. We stratified the population into
subsets with no prior TCZc use and ever TCZ use (see
Table 3, right columns). After removing prior TCZc
users, more comorbidities and non-TNF biologic use
demonstrated a significant association with future
TCZm use.
Discussion
While there are many good treatment options for RA,
the multitude of treatments has led to greater confusion.
Which treatments are best for which patients in which
order? These questions are complicated to approach but
must begin with an understanding of how different
treatments are sequenced in RA. We used a large real-
world data set from the Corrona RA registry to examine
methods for describing the path to a given treatment.
We embarked on this sequence analysis focusing on
TCZ, and specifically TCZm, as a “proof of concept”
study. We found several dominant sequences of treat-
ments that led to TCZm and some patient characteris-
tics associated with TCZm use over time, including
prior TCZc use, older age, longer disease duration, sero-
negative status, higher disease activity, and no immediate
Table 2 Transition between biologic DMARDs during Corrona follow-up, 2002–2019
First
bDMARD









































TCZ monotherapy 66 (0.90) 78 (1.08) 45 (0.70) 37 (0.64) 21 (0.41) 25 (0.54) 23 (0.55) 18 (0.48) 12 (0.36) 17 (0.56) 8 (0.29)
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TCZ tocilizumab; TNFi TNF inhibitors; nonTNF nonTCZ bDMARD, includes all JAK inhibitors, abatacept, and rituximab; DMARD disease-modifying anti-rheumatic
drugs; bDMARDs biologic DMARDs; csDMARDs conventional synthetic DMARDs
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past prior use of a TNF inhibitor. Further work will
analyze sequences of competing treatments.
The goal of these analyses was not to derive a better
treatment sequence (we did not focus on clinical out-
comes), but rather to develop ways of assessing se-
quences of DMARDs. The typical method for examining
comparative effectiveness in RA has focused on compar-
ing one drug with another, sometimes in randomized
controlled trials but often using observational epidemio-
logic methods [19, 20]. While comparing active drugs
with one another (versus placebo) is critical, the thera-
peutic armamentarium for RA has at least five dominant
mechanisms each with several agents. As the current
analyses demonstrate (Fig. 1 and Table 2), patients
switch drugs commonly. The switching to an option like
TCZm has strong correlates, including the use of spe-
cific prior DMARDs. Thus, to evaluate current practice,
sequential trials must be considered. For example, early
RA is typically responsive to multiple different therapies,
but the effectiveness of treatments after initial therapy
varies. Identifying patient characteristics (e.g., serologic
status, gender, disease duration, HLA status) that might
identify more or less successful treatment sequences
would assist clinicians and patients determine the next
treatment of choice. However, structuring these decision
nodes in a trial format requires an adaptive trial design.
Other implications follow from these findings. First,
the differences in predictors between baseline and
follow-up were subtle and somewhat to be expected.
The variables that became important during follow-up
were prior treatments and disease activity, emphasizing
the importance of DMARD sequence and DMARD re-
sponse. Second, the variables associated with TCZ and
TCZm use were not substantially different. This likely
reflects the fact that almost one-third of patients who try
TCZm have used TCZc, possibly because TCZm is simi-
larly effective to TCZc [12–15]. Third, the path to
TCZm typically takes 25.6 months and a median of 1
other bDMARD and up to 5 others. This illustrates the
tremendous amount of trial and error that is typical of
the treatment course for RA. Several factors may con-
tribute to the relative infrequent use of TCZm as first-
line bDMARD. First, in the USA, drug insurance often
dictates which drugs are used first-line as a bDMARD.
Fig. 2 Sequences of biologic DMARDs among patients in Corrona who eventually used TNF inhibitor monotherapy. Each colored line represents
a common sequence of treatments used by a subset of Corrona patients ending with TNF inhibitor monotherapy. For example, the left-most
yellow line illustrates the sequence TNF+NonBiologics->No recorded drug->NonBiologics->TNF+NonBiologics->TNF mono. The number of
markers on each line is equal to the number of treatments (combinations) in the trajectory, looking back at most 4 steps before TCZm treatment.
The thickness of a line correlates linearly with the number of patients following the corresponding sequence (with the exception of
TNF+NonBiologics->TNF mono which is scaled down for the plot). The colored legend describes the sequences of DMARD treatments for these
patients. Faint gray lines illustrate sequences with fewer than 5 occurrences. Abbreviations: Missing, no recorded drug use for 2 consecutive visits;
TNF, tumor necrosis factor (inhibitor); DMARD, disease modifying anti-rheumatic drug; bDMARD, biologic DMARD; mono, monotherapy
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The structure and rules of patients’ drug insurance is
not a variable contained in the Corrona database. Sec-
ond, it may be that rheumatologists are less comfortable
using TCZm since the drugs are newer to the market
than TNFi’s or abatacept. Finally, it is also possible that
patients are reluctant to use a drug that may worsen
their lipid profile.
While this study did not aim to define which treat-
ments are best for a given set of patients, we focused on
describing the complex sequence of RA treatments and
how patients transition between treatments toward
TCZm. TCZm is just one example of a bDMARD that
helps illustrate the haphazard treatment sequence that
patients with RA experience. We believe that there
needs to be a better framework for explicitly testing
treatment sequences in RA. The concept of the dynamic
treatment regime describes treatment decisions based on
patient states that are recognized to evolve over time
[21]. For example, early RA is typically responsive to
multiple different therapies, but the effectiveness of
treatments after initial therapy varies. Identifying patient
characteristics (e.g., serologic status, gender, disease dur-
ation, HLA status) that might identify more or less suc-
cessful treatment sequences would assist clinicians and
patients determine the next treatment of choice. How-
ever, structuring these decision nodes in a trial format
Table 3 Regression models predicting the use of tocilizumab monotherapy, odds ratios (95% confidence intervals)
Total population No prior tocilizumab combination (n
= 6821)






Baseline and follow-up Baseline and follow-up
Age, per year 0.99 (0.98,
1.00)
1.04 (1.00, 1.08) 1.03 (0.99, 1.07) 1.03 (1.00, 1.06)
Male vs. female 0.82 (0.61,
1.11)










2.82 (0.46, 17.2) 0.38 (0.07, 2.18) 1.36 (0.27, 6.69)
Missing 0.50 (0.29–
0.84)
9.58 (1.85, 49.7) 1.72 (0.39, 7.67) 0.99 (0.33, 3.03)
DMARD use**
csDMARD, baseline 0.48 (0.37–
0.63)
– – –
TCZ combination – 327 (80, 1343) – –
TNFi – 0.21 (0.09, 0.49) 0.28 (0.11, 0.73) 0.08 (0.03, 0.21)
nonTNFi nonTCZ
bDMARD
– 1.73 (0.86, 3.50) 2.70 (1.25, 5.85) 0.17 (0.07, 0.37)
Only csDMARD – 0.94 (0.36, 2.47) 1.16 (0.40, 3.39) 2.76 (1.18, 6.47)
No DMARDs – 0.05 (0.01, 0.16) 0.09 (0.03, 0.33) 0.02 (0, 0.12)
Glucocorticoid use – 0.74 (0.39, 1.40) 0.91 (0.46, 1.78) 0.91 (0.46, 1.78)
CDAI, severe – Reference Reference Reference
Moderate – 0.43 (0.23, 0.78) 0.41 (0.22, 0.79) 0.44 (0.17, 1.17)
Low – 0.39 (0.21, 0.74) 0.40 (0.20, 0.79) 0.70 (0.29, 1.70)
Remission – 0.17 (0.07, 0.42) 0.11 (0.04, 0.32) 0.53 (0.18, 1.52)
Comorbidities, count# – 1.04 (0.98, 1.11) 1.09 (1.01, 1.18) 1.01 (0.92, 1.11)
Notes: Odds ratios (95% confidence intervals). Baseline models used logistic regression. Models with follow-up data used mixed generalized linear regression
TCZ tocilizumab; DMARD disease-modifying anti-rheumatic drug; csDMARDs conventional synthetic DMARDs; nonTNFi nonTCZ bDMARD includes all JAK inhibitors,
abatacept, and rituximab
---Not considered at baseline or not significant in univariable screen so not considered in multivariable model or withheld from the model because of problems
with convergence
*Serologic status defined as a positive if either rheumatoid factor or anti-CCP antibody were ever positive up to the relevant reference point
**Reference category for DMARD use is the non-use of a give DMARD
#Comorbidities are noted in Table 1. Clinical disease activity index (CDAI) categories defined as remission (CDAI < 2.8), low (CDAI 2.9–10.0), moderate (CDAI 10.1–
22.0), and high (CDAI > 22.1)
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requires an adaptive trial design. An example of a
relatively simple dynamic treatment regime is the dos-
ing of warfarin over time in a patient with changing
clotting times and changing clinical characteristics. A
clinician considers the current state and prior states
to determine the optimal treatment at a given point
in time. The same set of issues, but slightly more
complicated, can be considered for RA treatment:
what are the patient’s current characteristics (e.g., dis-
ease activity), what are the prior characteristics (e.g.,
what treatments have been tried), and what are the
features of the patient’s disease (e.g., serologic status,
erosion status, disease duration).
The dynamic treatment regimens can be tested in the
setting of sequential multiple assignment randomized
(SMART) trials [22]. As the name implies, this type of a
randomized trial allows for sequences of treatments that
may be different across patient subgroups and are deter-
mined based on treatment response [23]. SMART trials
have grown in popularity but we are not aware of any
such trials occurring in RA.
The current set of analyses has important limitations.
Similar to most registries, Corrona has longitudinal data
but it is “left-censored,” people often enter as prevalent
cases of RA, and thus, we may not have full information
about their treatment history. Corrona is a very large
registry but represents patients with RA in rheumatology
practices. Thus, patients whose RA is cared for by pri-
mary care clinicians are not well represented. As noted,
we did not focus on clinical outcomes, making it impos-
sible for us to comment on which treatment is better or
worse for a given patient. Like all good science, this type
of analysis should be repeated in other datasets.
Strengths of the analysis include the large size of Cor-
rona, and the fact that it reflects real-world evidence.
The dataset contains many longitudinal variables, allow-
ing us to consider sequential predictors of DMARD
treatment. Including variables that change over time,
such as prior treatments and disease activity, had a
major impact on the regression coefficients. This sug-
gests that responses to treatment are critical for deter-
mining sequences of treatment.
Table 4 Regression models predicting the use of tocilizumab, either combination or monotherapy, using baseline only or baseline
and follow-up variables, odds ratios (95% confidence intervals)
Baseline only Baseline and follow-up
Age, per year 0.99 (0.98, 0.99) 1.05 (1.02, 1.08)
Male vs. female 0.91 (0.75, 1.11) 1.03 (0.48, 2.20)
Disease duration, years 0.99 (0.99, 1.01) 1.06 (1.03, 1.08)
Serologic status*
Negative Reference Reference
Positive 0.66 (0.56–0.78 0.11 (0.04, 0.29)
Missing 0.42 (0.29–0.60) 0.88 (0.38, 2.06)
DMARD use**
csDMARD, baseline 0.71 (0.59–0.86) 0.18 (0.12, 0.27)
TNFi – 0.48 (0.26, 0.90)
nonTNFi nonTCZ bDMARD – 4.59 (2.91, 7.25)
Only csDMARD – 5.83 (3.73, 9.13)
No DMARDs – 0.40 (0.18, 0.88)
Glucocorticoid use – 0.87 (0.61, 1.23)
CDAI, Severe – Reference
Moderate – 0.65 (0.46, 0.91)
Low – 0.48 (0.33, 0.70)
Remission – 0.20 (0.11, 0.37)
Comorbidities, count# – 1.16 (1.11, 1.22)
Notes: Odds ratios (95% confidence intervals). Baseline models used logistic regression. Models with follow-up data used mixed generalized linear regression
TCZ tocilizumab; DMARD disease-modifying anti-rheumatic drug; csDMARDs conventional synthetic DMARDs; nonTNFi nonTCZ bDMARD includes all JAK inhibitors,
abatacept, and rituximab
---Not considered at baseline or not significant in univariable screen so not considered in multivariable model or withheld from the model because of problems
with convergence
*Serologic status defined as a positive if either rheumatoid factor or anti-CCP antibody were ever positive up to the relevant reference point
**Reference category for DMARD use is the non-use of a give DMARD
#Comorbidities are noted in Table 1. Clinical disease activity index (CDAI) categories defined as remission (CDAI < 2.8), low (CDAI 2.9–10.0), moderate (CDAI 10.1–
22.0), and high (CDAI > 22.1)
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In conclusion, we examined sequences of RA treat-
ments in a large USA-based real-world dataset, focusing
on TCZm. We characterized time until TCZm, domin-
ant paths to TCZm, and longitudinal predictors of
TCZm. This work highlights the variable treatment se-
quences experienced by patients with RA starting a
bDMARD. This variability is likely because of an evi-
dence deficit regarding the comparative effectiveness of
different treatment sequences in RA. While observa-
tional datasets may provide useful information regarding
dynamic treatment regimes, it is more likely that SMAR
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